Oxford and AstraZeneca’s Covid-19 vaccine to be trialed AGAIN amid mounting questions over dosage issues
The Covid-19 vaccine being developed by Oxford University and AstraZeneca will be tested again, the drug maker’s CEO said on Thursday, following growing doubts over the jab, due to dosing and data-handling errors.
The British-Swedish pharmaceutical giant is to run a fresh trial of its candidate vaccine at a lower dosage, which the company earlier claimed had performed better than a full dosage. “Now that we’ve found what looks like a better efficacy we have to validate this, so we need to do an additional study,” AstraZeneca CEO Pascal Soriot told Bloomberg.
He added that it would likely be an “international study, but this one could be faster because we know the efficacy is high so we need a smaller number of patients.”
*** This article has been archived for your research. The original version from David Icke can be found here ***
